22 mayo 2018

YONDELIS MEJOR EN 2ª LINEA STS YA QUE ESTABILIZA LA ENFERMEDAD A LARGO PLAZO Y CON MENOS EFECTOS SECUNADRIOS QUE GEMCITABINE O DOCETAXEL .

Los Agentes para la Segunda línea y Líneas adicionales incluyen Trabectedin , que combina estabilización tumoral a largo plazo con buena calidad de vida, y Gemcitabina + Docetaxel que puede producir una respuesta clínica marcada, aunque a costa de una Alta Toxicidad .


Getting up-to-date in the Management of Soft Tissue Sarcoma .

Jean-Yves Blay // Published Online:16 May 2018.


Surgery (+ radiation therapy in selected cases) is standard treatment for adult-type localized soft tissue sarcoma (STS). Accumulating randomized clinical evidence also supports adjuvant chemotherapy as a treatment option, although this remains contentious.

Doxorubicin (± ifosfamide) is the standard first-line systemic treatment for advanced STS; however, newer chemotherapeutic agents may improve outcomes achieved with single-agent doxorubicin.

In a Phase II study, adding olaratumab to doxorubicin markedly improved overall survival.

Agents for second- and further lines include trabectedin, which combines long-term tumor stabilization with good quality of life, and gemcitabine + docetaxel which can produce a marked clinical response although at the cost of high toxicity.

Pazopanib, eribulin, aldoxorubicin and regorafenib are other options for use in advanced STS.